SELF-ADMINISTRATION OF IN-PATIENT MEDICATIONS: A PILOT STUDY IN CHILDREN WITH CYSTIC FIBROSIS

Khola Khan1, Aoife Harrington1, Rupinder Pannu1

  • 1Royal Brompton & Harefield NHS Foundation Trust.

Insights

The Self-Administration Of Medicines Scheme (SAM) empowers children with Cystic Fibrosis (CF) and their families to manage medications, improving independence and reducing costs. This pilot program showed positive reception and significant cost savings, leading to its wider implementation.

Area of Science:

  • Pediatric pulmonology
  • Healthcare management
  • Patient empowerment

Background:

  • Children with Cystic Fibrosis (CF) require complex medication regimens.
  • Parent/carer administration is typical until children are older.
  • Hospitalization often shifts administration to nurses, potentially disempowering patients and families.

Purpose of the Study:

  • To implement and evaluate the Self-Administration Of Medicines Scheme (SAM) for all pediatric CF admissions.
  • To empower patients/parents/carers in medication administration.
  • To reduce nursing workload, educate families, and achieve cost savings through Patients Own Medicines (PODs).

Main Methods:

  • Developed and approved a policy and training program for SAM.
  • Assessed all admitted CF families for participation over 10 months.
  • Collected data via questionnaires for patient/parent/carer and nurse feedback, and POD re-use for cost analysis.

Main Results:

  • 95 out of 159 (60%) CF admissions were assessed for SAM; 64 participated.
  • Participants reported benefits including reduced waiting times for medication, increased independence, and routine maintenance.
  • Nurses reported reduced administration time and pressure; significant cost savings of £1023 per patient over 3 months were observed with PODs.

Conclusions:

  • The SAM pilot scheme was well-received by patients, parents/carers, and staff.
  • The scheme facilitated greater engagement in medication administration and demonstrated cost-effectiveness.
  • SAM will be extended to all patients on the ward due to its success.
Abstract

Keywords:
AbstractOral

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
603
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
636
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
959
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312